All authors were involved in the writing, reviewing and editing of the manuscript, gave final approval and agreed to be accountable for all aspects of the work. ORCID Lene Jensen http://orcid.org/0000-0002-7111-2486 Julie B. Hjerpsted http://orcid.org/0000-0002-6938-786X REFERENCES 1. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. Management of type 2 diabetes: new and future developments in treatment.Lancet. 2011; 378:182-197. 2. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the cur- rent and future costs of type 1 and type 2 diabetes in the UK, includ- ing direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855-862. 3. International Diabetes Federation.IDF Diabetes Atlas. 7th ed. ; 2015. https://www.idf.org/e-library/epidemiology-research/diabetes-atlas/ 13-diabetes-atlas-seventh-edition.html. Accessed June 8, 2017. 4. Halban PA, Polonsky KS, Bowden DW, et al. ÃŸ-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.Diabetes Care. 2014;37:1751-1758. 5. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis.Diabetes Obes Metab. 2017;19:524-536. 6. Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1receptor agonists.Diabetes Obes Metab. 2016;18:317-332. 7. Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.J Med Chem. 2015;58:7370-7380. 